Newer Treatments

At least in the short-term, the newer treatments below bring a greater possibility for some amount of visual recovery to those of us who have experienced substantially decreased vision due to macular edema. Some of these treatments may also help to prevent or treat neovascularization. But many questions about these newer treatments are still being explored. How well do they work in the long term? Do they provide any visual improvement for ischemic CRVO? Do they help prevent neovascular complications? What are their side effects in the eye and in the rest of the body?

Click on charts to expand:                                 What are “letters”?       

 

 

 

Intravitreal Anti-VEGF Treatments:

 

·         Avastin (bevacizumab)

o   Macular Edema - Bevacizumab has been widely reported to be of value in reducing the anatomic and visual effects of macular edema in CRVO as well as a number of other eye conditions. PubMed Searches:  [CRVO only]  [BRVO]  [DME]  [Other Conditions]

o   Neovascularization - Bevacizumab has been widely reported to be a valuable tool in helping to combat neovascularization occurring after CRVO as well as in other eye conditions. PubMed Searches:  [RVO only]  [Neovascular Glaucoma]  [Other Eye Conditions]

 

·         Lucentis (ranibizumab)

o   [Highlights of Prescribing Information]

o   CRUISE - Phase III trial for macular edema secondary to Central RVO

§  [Trial Description]  [Abstract]  [Synopsis]  [Press Release]  [Notes on Phase III Trial]

o   PubMed Searches: [RVO Only] [Other Conditions]

 

·         Eylea (VEGF Trap-Eye; aflibercept)

o   COPERNICUS - Phase III Trial in CRVO - [Press Release] [Trial Description]

o   GALILEO - Phase III Trial in CRVO - [Press Release] [Trial Description]

o   PubMed Searches: [Eye Conditions]

o   [Investor Presentation]

 

·         Macugen (pegaptanib sodium)

o   Phase II Trial in CRVO: [Trial Description]  [Abstract]  [Free Full Text]  [Notes on Trial]

o   PubMed Searches: [RVO Only]  [DME]  [Other Eye Conditions]

 

Intravitreal Steroid Treatments:

 

·         Triamcinolone Acetonide (IVTA)

o   SCORE-CRVO study - [Trial Description[Abstract]  [Free Full Text]  [Notes on SCORE]

o   PubMed Searches: [RVO only]  [DME]  [Other Eye Conditions]

 

·         Ozurdex - an intravitreal implant that provides sustained release of dexamethasone.

o   [Highlights of Prescribing Information] - includes information on side effects.

o   Pooled data from 2 Phase III Trials (CRVO & BRVO): [Trial Descriptions 2]  [Abstract]

o   GENEVA Study - [RVO Clinical Results Data] - use the menu underneath “Clinical Profile” to page through the various sections. Includes information on increased eye pressure and cataract progression.

o   PubMed Searches: [Ozurdex]

 
 

References

1 - Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun;117(6):1124-1133. [PubMed]

2 - Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.  Ophthalmology. 2010 Jun;117(6):1102-1112. [PubMed]

3 - Regeneron Press Release Dated 12/20/10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME). As accessed 5/8/11. [Link]

4 - Regeneron Press Release Dated 4/27/11. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion. As accessed 5/8/11. [Link]

5 - Investor Presentation Dated 2/13/11. Investor Briefing at Bascom Palmer Angiogenesis 2011. (95 pages). As downloaded 5/8/11. [Link]

6 - Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM; Pegaptanib in Central Retinal Vein Occlusion Study Group. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.  Arch Ophthalmol. 2009 Apr;127(4):374-80. [PubMed]

7 - Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009 Sep;127(9):1101-14. [PubMed]  [Free Full Text]

8 - Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009 Sep;127(9):1115-28. [PubMed]  [Free Full Text]

9 - Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146. [PubMed]

10 - Ozurdex.com. CRVO patients: Mean change from baseline BCVA. As accessed 5/8/11. [Link]


Disclaimer: Since I am only a fellow patient and have no medical background you should not base any of your medical decisions on these notes or videos. Seek the advice of a competent medical professional promptly before making medical decisions.

Copyright © 2011, crvo_my